Acorda Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2010 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Acorda Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2010 to Q1 2024.
  • Acorda Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$27.4M, a 62.8% decline year-over-year.
  • Acorda Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$263M, a 352% decline year-over-year.
  • Acorda Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$253M, a 284% decline from 2022.
  • Acorda Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$65.9M, a 36.6% increase from 2021.
  • Acorda Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$104M, a 4.38% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$263M -$27.4M -$10.6M -62.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$253M -$218M -$237M -1238% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$16M -$8.89M +$4.97M +35.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$20.9M -$9.38M +$37.3M +79.9% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-14
Q1 2023 -$58.2M -$16.8M +$7.7M +31.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$65.9M $19.1M +$39.7M Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$106M -$13.9M +$13.2M +48.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$119M -$46.7M -$23.8M -104% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$95M -$24.5M +$8.93M +26.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$104M -$20.6M +$62.5M +75.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 -$166M -$27.1M -$34.4M -468% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$132M -$22.9M -$5.44M -31.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$127M -$33.5M -$27M -417% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 -$99.6M -$83M -$149M -226% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-18
Q3 2020 $49.1M $7.35M +$271M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$222M -$17.4M +$10.1M +36.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$232M -$6.47M +$41.1M +86.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 -$273M $65.7M +$56.1M +584% Oct 1, 2019 Dec 31, 2019 10-K 2020-02-28
Q3 2019 -$329M -$264M -$250M -1794% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$79.4M -$27.5M -$73.7M -159% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$5.72M -$47.6M -$39.4M -481% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 $33.7M $9.6M +$181M Oct 1, 2018 Dec 31, 2018 10-K 2020-02-28
Q3 2018 -$147M -$13.9M +$11.3M +44.8% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-28
Q2 2018 -$158M $46.2M +$54.4M Apr 1, 2018 Jun 30, 2018 10-K 2020-02-28
Q1 2018 -$213M -$8.2M +$10.7M +56.6% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-28
Q4 2017 -$223M -$171M -$168M -5429% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 -$55.4M -$25.2M -$12.2M -93.3% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-27
Q2 2017 -$43.2M -$8.2M +$10.8M +56.8% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-27
Q1 2017 -$54M -$18.9M -$18.4M -3535% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-27
Q4 2016 -$35.6M -$3.09M -$12.3M -134% Oct 1, 2016 Dec 31, 2016 10-K/A 2018-03-09
Q3 2016 -$23.3M -$13M -$17M -431% Jul 1, 2016 Sep 30, 2016 10-K/A 2018-03-09
Q2 2016 -$6.33M -$19M -$20M -2001% Apr 1, 2016 Jun 30, 2016 10-K/A 2018-03-09
Q1 2016 $13.6M -$520K +$2.57M +83.1% Jan 1, 2016 Mar 31, 2016 10-K/A 2018-03-09
Q4 2015 $11.1M $9.21M +$8.87M +2681% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-27
Q3 2015 $2.18M $3.94M -$8.01M -67% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-27
Q2 2015 $10.2M $997K -$3.69M -78.7% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-27
Q1 2015 $13.9M -$3.09M -$3.79M -539% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-27
Q4 2014 $17.7M $331K -$5.86M -94.7% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-29
Q3 2014 $23.5M $12M +$4.48M +59.9% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-29
Q2 2014 $19.1M $4.69M +$775K +19.8% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-29
Q1 2014 $18.3M $703K +$1.84M Jan 1, 2014 Mar 31, 2014 10-K 2016-02-29
Q4 2013 $16.4M $6.19M -$127M -95.3% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-27
Q3 2013 $143M $7.48M -$2.12M -22.1% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-27
Q2 2013 $145M $3.91M -$635K -14% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-27
Q1 2013 $146M -$1.14M -$8.99M -115% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-27
Q4 2012 $155M $133M +$120M +948% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-03
Q3 2012 $34.7M $9.59M -$9.27M -49.1% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-03
Q2 2012 $44M $4.55M +$4.83M Apr 1, 2012 Jun 30, 2012 10-K 2014-03-03
Q1 2012 $39.1M $7.85M +$8.52M Jan 1, 2012 Mar 31, 2012 10-K 2014-03-03
Q4 2011 $30.6M $12.7M +$9.02M +246% Oct 1, 2011 Dec 31, 2011 10-K 2013-02-28
Q3 2011 $21.6M $18.9M +$6.43M +51.7% Jul 1, 2011 Sep 30, 2011 10-K 2013-02-28
Q2 2011 $15.2M -$285K +$6.48M +95.8% Apr 1, 2011 Jun 30, 2011 10-K 2013-02-28
Q1 2011 $8.67M -$672K +$20.4M +96.8% Jan 1, 2011 Mar 31, 2011 10-K 2013-02-28
Q4 2010 -$11.8M $3.67M Oct 1, 2010 Dec 31, 2010 10-K 2012-02-28
Q3 2010 $12.4M Jul 1, 2010 Sep 30, 2010 10-K 2012-02-28
Q2 2010 -$6.76M Apr 1, 2010 Jun 30, 2010 10-K 2012-02-28
Q1 2010 -$21.1M Jan 1, 2010 Mar 31, 2010 10-K 2012-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.